## Rosalinda Allegro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6159405/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology, 2005, 65, 65-69.	0.5	45

Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter doubleâ€blinded randomized study between single or combination therapy (PROCOMB) Tj ETQq0 0 0 ngBT /Overslock 10 Tf

3	PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. Prostate Cancer and Prostatic Diseases, 2008, 11, 148-152.	2.0	38
4	TUR and Adjuvant Intravesical Chemotherapy in T1G3 Bladder Tumors: Recurrence, Progression and Survival in 137 Selected Patients Followed Up to 20 Years. European Urology, 2004, 45, 730-736.	0.9	33
5	A 1â€year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk nonâ€muscleâ€invasive bladder cancer. BJU International, 2010, 106, 212-217.	1.3	28
6	A Randomized Trial Comparing Tamoxifen Therapy vs. Tamoxifen Prophylaxis in Bicalutamide-Induced Gynecomastia. Clinical Genitourinary Cancer, 2012, 10, 174-179.	0.9	18
7	Preliminary Report of a Multicentric Study on Environmental Risk Factors in Ta-T1 Transitional Cell Carcinoma of the Bladder. Urologia Internationalis, 2006, 77, 152-158.	0.6	17
8	Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Non–muscle-invasive Bladder Carcinoma. Urology, 2013, 81, 277-282.	0.5	17
9	Prediction by quantitative histology of pathological stage in prostate cancer. European Journal of Surgical Oncology, 2005, 31, 309-313.	0.5	16
10	Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression. Clinical Genitourinary Cancer, 2019, 17, e751-e758.	0.9	12
11	Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma. Journal of Cancer Research and Clinical Oncology, 2003, 129, 472-476.	1.2	9
12	Multiplicity and History Have a Detrimental Effect on Survival of Patients With T1G3 Bladder Tumors Selected for Conservative Treatment. Journal of Urology, 2008, 180, 886-891.	0.2	9
13	Risk Assessment of Cadmium, Lead, and Mercury on Human Health in Relation to the Consumption of Farmed Sea Bass in Italy: A Meta-Analytical Approach. Frontiers in Marine Science, 2021, 8, .	1.2	8
14	Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study. BJU International, 2003, 92, 545-550.	1.3	6
15	Cigarette Smoking and Drinking Water Source: Correlation with Clinical Features and Pathology of Superficial Bladder Carcinoma. Urologia Internationalis, 2009, 82, 318-323.	0.6	6
16	Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital. Urologia Internationalis, 2009, 83, 452-457.	0.6	5
17	Medial tunica degeneration of the ascending aortic wall is associated with specific microRNA changes in bicuspid aortic valve disease. Molecular Medicine Reports, 2021, 24, .	1.1	5
18	Is Free/Total PSA Predictive of Pathological Stage and Gleason Score in Patients with Prostate Cancer and Serum PSA â‰犂0 ng/ml?. Urologia Internationalis, 2006, 76, 232-235.	0.6	4

Rosalinda Allegro

#	Article	IF	CITATIONS
19	The assessment of the attitude of Sicilian consumers towards wild and farmed seafood products – a sample survey. British Food Journal, 2021, 123, 2506-2536.	1.6	4
20	Prevention of topic toxicity of BCG with single-dose prulifloxacin. Preliminary results of a randomized pilot study. Urologia, 2010, 77, 240-247.	0.3	3
21	Validation of a Commercial Loop-Mediated Isothermal Amplification (LAMP)-Based Kit for the Detection of Salmonella spp. According to ISO 16140:2016. Applied Sciences (Switzerland), 2021, 11, 6669.	1.3	3
22	Is PSA density still useful in diagnosing prostate cancer?. Archivio Italiano Di Urologia Andrologia, 2009, 81, 199-202.	0.4	3
23	A RANDOMISED STUDY EVALUATING MAINTENANCE SCHEDULE IN EARLY ADJUVANT CHEMOTHERAPY FOR INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER. European Urology Supplements, 2008, 7, 298.	0.1	1
24	A RANDOMIZED TRIAL COMPARING TAMOXIFEN THERAPY VERSUS TAMOXIFEN PROPHYLAXIS IN BICALUTAMIDE INDUCED GYNAECOMASTIA. Journal of Urology, 2008, 179, 181-181.	0.2	1
25	Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy. Urology Annals, 2015, 7, 21.	0.3	1
26	University Performance Before and During Economic Crises. UNIPA Springer Series, 2020, , .	0.1	1
27	EFFICACY OF ONE-YEAR MAINTENANCE IN EARLY ADJUVANT CHEMOTHERAPY FOR INTERMEDIATE RISK NON-MUSCLE- INVASIVE BLADDER CANCER. RESULTS AT 24 MONTHS OF A RANDOMIZED TRIAL. Journal of Urology, 2008, 179, 584-584.	0.2	0
28	OUT-PATIENT LOW-DOSE ORAL CHEMOTHERAPY IN HORMONE REFRACTORY PROSTATE CARCINOMA (HRPC) PATIENTS UNFIT FOR HOSPITAL ADMITTANCE. Journal of Urology, 2008, 179, 183-183.	0.2	0
29	Conservative Management and Survival of Patients Affected by T1G3 Bladder Tumours. When Shall we Indicate it and When the Cystectomy?. Urologia, 2009, 76, 31-35.	0.3	0
30	Results at 48 Months of a Randomized Trial on Maintenance after Early Adjuvant. Urologia, 2009, 76, 27-30.	0.3	0
31	Low-Risk Bladder Tumors: How Accurate are the EORTC Risk Tables?. Urologia, 2009, 76, 36-38.	0.3	0
32	1467 MAINTENANCE IS OF LIMITED EFFICACY AFTER EARLY ADJUVANT CHEMOTHERAPY FOR INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER. RESULTS AT 48 MONTHS OF A RANDOMIZED TRIAL. Journal of Urology, 2010, 183, .	0.2	0
33	1175 LONG TERM OUTCOME OF PATIENTS FOLLOWED FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMI-BC) PRESENTING WITH POSITIVE NMP22 AND NEGATIVE CYTOLOGY AND CYSTOSCOPY. Journal of Urology, 2010, 183, .	0.2	0
34	The Multicriteria Electre III Model Applied to the Evaluation of the Placement of University Graduates. Contributions To Statistics, 2011, , 175-194.	0.2	0
35	PD23-07 SERENOA REPENS, LYCOPENE AND SELENIUM VS. TAMSULOSIN IN THE TREATMENT OF LUTS / BPH: AN ITALIAN MULTICENTER RANDOMIZED COMPARATIVE STUDY BETWEEN SINGLE OR COMBINATION THERAPIES. (PROCOMB STUDY). Journal of Urology, 2014, 191, .	0.2	0
36	MP45-10 CORRELATION BETWEEN FIBRONECTIN GENE EXPRESSION AND LOCAL TOXICITY INDUCED BY ADJUVANT INTRAVESICAL THERAPY. Journal of Urology, 2015, 193, .	0.2	0

#	Article	IF	CITATIONS
37	377: Distribution of Smoking, Water Resource and Other Environmental Factors in Patients Affected by Superficial Bladder Cancer. Journal of Urology, 2004, 171, 99-99.	0.2	Ο
38	38: Drinking Water Source and Cigarette Smoking in Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2006, 175, 13-14.	0.2	0
39	Main Results. UNIPA Springer Series, 2020, , 19-29.	0.1	0
40	About Overeducation and Mismatching. UNIPA Springer Series, 2020, , 3-6.	0.1	0
41	Comments and Final Remarks. UNIPA Springer Series, 2020, , 31-33.	0.1	0